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including those derived from metastases, 
show preferential expression of functional 
HIF-2α over HIF-1α. Additionally, a fur-
ther increase in HIF-2α levels enhances 
growth of renal cancer xenograft s, whereas 
overexpression of HIF-1α inhibits it.10,11
Diff erences in HIF isoform expression 
and function are also manifest in other 
tumor types, presumably refl ecting the 
net selective advantage of the particular 
spectrum of downstream genes activated 
in a particular cellular background by 
environmental factors. In tumors derived 
from ES cells, variable eff ects of loss of 
HIF-1α expression on solid tumor growth 
have been reported, probably depending 
on the balance of eff ects on microenvi-
ronmental hypoxia, apoptosis, and stress-
induced proliferation.12,13 More recently, 
studies on teratomas derived from ES 
cells in which an HIF-2α allele has been 
knocked in at the HIF-1α locus indicate 
that HIF-2α promotes tumor growth 
more eff ectively than HIF-1α.14 In keep-
ing with this, a recent study of melanoma 
patients has reported that, in multivariate 
analysis, HIF-2α staining is an independ-
ent indicator of poor prognosis whereas 
HIF-1α staining is not.15
Tumor development often involves 
reversion to a fetal or embryonic cel-
lular phenotype, with earlier markers 
generally indicating a more aggressive 
phenotype. In the fetal kidney, tubular 
HIF-1α expression is seen in normoxia, 
but this disappears once nephrogenesis is 
complete. Whether HIF-2α contributes 
at an earlier stage of renal development 
than that studied by Bernhardt et al.3 is 
unknown. However, the role of HIF-2 in 
renal vasculogenesis that they describe is 
of particular interest given the highly vas-
cular nature of VHL-associated tumors.
Understanding the functional dif-
ferences between the HIFα isoforms 
and their roles in tumor formation is 
a prerequisite for attempts to manipu-
late this important homeostatic mecha-
nism to therapeutic advantage, be that 
to enhance endogenous erythropoietin 
production, aff ect tumor growth, facili-
tate therapeutic angiogenesis in ischemic 
tissues, or help preserve tissues for trans-
plantation. Th e work reported here by 
Bernhardt et al.3 represents another 
important contribution in dissecting 
the developmental, physiological, and 
pathological roles of HIF.
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Acute renal failure outcomes in 
children and adults
J Radhakrishnan1 and K Kiryluk1
Acute renal failure (ARF) in hospitalized patients remains associated 
with significant morbidity and mortality. Most reports have detailed 
the in-hospital outcomes in ARF patients. This commentary focuses on 
the outcomes (including quality of life) of ARF patients, both adults and 
children, after discharge from the hospital.
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With rapid advances in medical tech-
nology, the epidemiology of acute renal 
failure (ARF) has dramatically changed. 
Over the past few decades, obstetrical 
and traumatic causes of ARF have con-
tinued to decline, with a correspond-
ing increase in the number of elderly 
patients with complicated medical and 
surgical conditions.1 Th us, the typical 
ARF patient at this time possesses a large 
burden of comorbid illnesses and exten-
sive extrarenal complications.2 Despite 
major advances in dialysis and continu-
ous renal replacement therapies, the 
mortality rate from ARF has not changed. 
Th e adult mortality rates average approx-
imately 50% and have remained stable 
over the past 50 years.3 Th e outcome is 
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worse in the intensive care setting, where 
ARF frequently coincides with the mul-
tiorgan dysfunction syndrome.4 A large 
prospective multinational study of ARF 
in critically ill adults (Beginning and 
Ending Supportive Th erapy for the Kid-
ney; BEST Kidney) reported an overall 
in-hospital mortality rate of over 60%. 
Among the survivors, 13% were dialy-
sis dependent at discharge.5 Th e preva-
lence of in-hospital ARF remains high. 
In a recent prospective study of 4622 
patients admitted to the medical and 
surgical services of an urban tertiary 
care hospital, 7.2% of patients developed 
some degree of renal insuffi  ciency dur-
ing their hospitalization.6 Similarly, the 
prevalence of ARF in patients admitted 
to an intensive care unit was 5.7% in the 
BEST Kidney study recently reported.5
Th ere is a paucity of multicenter stud-
ies describing the epidemiology of ARF 
in children. As a result, what is known 
about pediatric ARF is extremely varied 
and largely reflects the population of 
children seen at a particular center. In 
addition, there are substantial geographic 
diff erences in the etiology of ARF. A 2005 
report from Houston, Texas, stated that 
the most common causes of ARF in hos-
pitalized children were renal ischemia 
(21%), pharmacologic agents (16%), and 
sepsis (11%), with primary renal disease 
accounting for only 7% of all the cases.7 
In this study, the most prevalent etiology 
of ARF in neonates was renal ischemia 
associated with congenital heart disease. 
Renal ischemia was also predominant in 
infants and toddlers, whereas nephro-
toxic medications were most commonly 
associated with ARF in older children 
and adolescents. In contrast, a study from 
Leeds, United Kingdom, reported that 
hemolytic uremic syndrome accounted 
for 45% of all pediatric cases of ARF. As 
in the Texas study, ischemia due to car-
diac surgery was the most common cause 
of ARF in neonates.8
Although reported mortality rates 
in pediatric ARF are typically 10–20% 
lower than in adults, some of the trends 
in ARF epidemiology are similar. As 
in adults, the mortality in children has 
not improved over the past few decades. 
Recent studies report in-hospital death 
rates of 30–46%7,9, which is similar to 
the 20–33% described in the 1970s.10 
As expected, the mortality is highest 
when ARF coexists with multiorgan 
dysfunction syndrome and exceeds 48% 
in children requiring renal replacement 
therapy.11 Th e survival is better in the 
group with primary renal disease as com-
pared with ARF secondary to systemic 
disease.9 Among critically ill children, 
the most important predictors of mortal-
ity include the severity of the underlying 
systemic illness, hemodynamic stability, 
and the degree of fl uid overload at initia-
tion of renal replacement therapy.11
In children who live in developing 
countries, ARF results mainly from 
infectious causes including gastroen-
teritis and malaria.12–14 A lack of access 
to medical care, poverty, and the use of 
herbal medications contribute to the 
poor outcome in these patients, with 
mortality rates approaching 40–60%.13,14 
Although only 22% of patients requiring 
dialysis were able to receive it, the real 
tragedy was that in a large proportion 
of ARF patients in developing countries 
prerenal causes prevailed, and were 
preventable through simply providing 
timely volume repletion.14,15
Although the immediate complica-
tions and mortality of ARF are well 
described in both children and adults, 
only a few studies report on long-term 
outcome and degree of residual renal 
impairment in the surviving patients. 
Such studies require an extended fol-
low-up period and are generally more 
diffi  cult to perform. In a study from Fin-
land on survivors of ARF who needed 
renal replacement, the mortality was 
41% at 28 days, 57% at 1 year, and 70% 
at 5 years.16 A retrospective longitudinal 
study followed 267 adult ARF survivors 
requiring short-term continuous renal 
replacement therapy. Renal insuffi  ciency 
persisted in 41% of the patients, 10% of 
patients required chronic dialysis, and 
the overall 5-year post-discharge sur-
vival was 50%.6 Th e pediatric popula-
tion, likewise, has not been studied 
extensively. In children surviving the 
hemolytic uremic syndrome, at the end 
of a median follow-up of 5 years, the 
proportion of children with renal seque-
lae such as proteinuria greater than or 
equal to 300 mg/l, hypertension, or a 
GFR less than 80 ml/min 1.73 m2 was 
23%.17 Abitbol et al reported on the 
long-term outcome of ARF in 20 pre-
term infants. Th e degree of proteinuria 
and creatinine elevation at 1 year of life, 
as well as a tendency toward obesity, cor-
related with progression to chronic renal 
insuffi  ciency, which occurred in 9 of the 
20 infants over 18 years of follow-up.18
An important issue for the long-term 
ARF survivor is quality of life. In a study 
looking at ARF survivors from two terti-
ary care centers in Australia and Italy, 
68.5% were satisfi ed with their present 
state of health, even though 60.6% stated 
that their mobility had been affected 
(41.9% were unable to walk more than 
200 m). Th e approximate cost for each 
year of survival was US$50,000. Most 
survivors (94%) stated that their treat-
ment was worthwhile, and the majority 
felt that they would undergo the same 
treatment again if necessary.19 In the 
Finnish study cited above, the investiga-
tors used the EuroQol (EQ-5D) instru-
ment to evaluate the patient’s perceived 
health. The EQ-5D score was signifi-
cantly lower in the study population than 
in the age- and gender-matched Finnish 
population (0.68 versus 0.86). Quality-
adjusted survival, too, was poor, with 
15 quality-adjusted life years per 100 
patients in the fi rst year of follow-up.16
In this issue, Askenazi et al20 present 
the longitudinal follow-up data on the 
original cohort from Texas, described 
by Hui-Stickle et al7 Th e authors retro-
spectively followed 248 children with 
hospital-acquired ARF over a period 
of 3–5 years. The in-hospital mortal-
ity rate was 29%. Th ere were 174 survi-
vors; 35 (20%) died aft er discharge (the 
causes of death were not analyzed), and 
97 (over 50%) were lost to follow-up or 
refused to participate in the study. Of 
the remaining 42 patients, 9 developed 
stage 1 chronic kidney disease, 4 devel-
oped stage 2 chronic kidney disease, and 
13 progressed to end-stage renal dis-
ease. Microalbuminuria was present in 8 
patients, hypertension in 6 patients, and 
microscopic hematuria in 1 patient. Th e 
true incidence of chronic kidney disease 
and other markers of renal dysfunction 
(microalbuminuria and hypertension) in 
the surviving population is not known, as 
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more than half of the potential subjects 
refused or were lost to follow-up. Despite 
these limitations and a relatively short 
follow-up period, the overall mortality 
and the incidence of end-stage renal dis-
ease were impressively high. Although 
the children themselves did not feel that 
their quality of life was aff ected, parents 
of children with ARF scored their chil-
dren much lower than did parents of 
healthy children.
As in adults, the diagnosis of ARF 
is becoming increasingly common in 
hospitalized children and carries a 
signifi cant burden of long-term mor-
tality, morbidity, and impaired quality 
of life. The study by Askenazi et al20 
is an important milestone in defi ning 
the long-term outcome of ARF and 
hopefully will pave the way for larger 
prospective studies with longer follow-
up periods. Th e progressive nature of 
post-ARF chronic kidney disease is an 
important observation, and close fol-
low-up of ARF survivors, particularly 
within the first 3–5 years, should be 
undertaken; such patients may benefi t 
from early referral to a nephrologist.
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